Who is sponsoring SorCape?

SorCape is sponsored by University of Florida.

What condition does SorCape study?

SorCape studies Colorectal Cancer Metastatic.

What drugs are being tested in SorCape?

Interventions: Sorafenib Plus Capecitabine (SorCape).

What is the status of SorCape?

SorCape is currently COMPLETED.

Last reviewed 2020-07-21 · How we verify

Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer

NCT01471353 Phase 2 COMPLETED Results posted

Combining Sorafenib with standard cytotoxic fluoropyrimidine therapy for advanced colorectal cancer may provide clinical benefit when no other treatment remains.

Details

Lead sponsor	University of Florida
Phase	Phase 2
Status	COMPLETED
Enrolment	43
Start date	2011-11
Completion	2017-05

Conditions

Colorectal Cancer Metastatic

Interventions

Sorafenib Plus Capecitabine (SorCape)

Primary outcomes

Sorafenib Activity — 2 years
Determine activity of sorafenib plus capecitabine on progression free survival (PFS) in patients with advanced colorectal cancer. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Countries

United States